Chairpersons: Prof. G. Minotti (ESC), Prof. J.-L. Zamorano (ESC), Dr C. Gottfridsson (AstraZeneca)
Objectives of the workshop
Cardio-oncology is the discipline that focuses on mechanisms and clinical manifestations of cardiovascular toxicity induced by cancer therapies.
Oncologists, haematologists, and radiation therapists are constantly faced with the risk of cardiovascular events in cancer patients. Old drugs are increasingly combined with or replaced by newer drugs, and hence cancer patients often present with a blend of toxicities. Furthermore, avalanches of new drugs are running in the pipeline of pharmaceutical companies, which anticipates the emergence of new clinical phenotypes of cardiovascular toxicity in the next few years. This calls for devising optimal but sustainable strategies of patient surveillance and prevention of cardiovascular events. ESC is committed to promoting knowledge and awareness for all stakeholders in cardio-oncology (doctors, patients, caregivers, drug developers).
The aim of this workshop is to review main cardio-oncology issues from preclinical, clinical, and regulatory issues, thereby fostering cross-fertilization between academic and industrial parties. New avenues to patient advocacy and research funding opportunities will also be explored